Research programme: ligand-conjugated antisense-based therapeutics - Ionis Pharmaceuticals

Drug Profile

Research programme: ligand-conjugated antisense-based therapeutics - Ionis Pharmaceuticals


Latest Information Update: 24 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Ionis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action ANGPTL3 protein inhibitors; Apolipoprotein A inhibitors; Apolipoprotein C-III inhibitors; RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acromegaly; Beta-thalassaemia; Dyslipidaemias; Hyperlipoproteinaemias; Hypertriglyceridaemia; Resistant hypertension

Most Recent Events

  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
  • 31 Dec 2014 Isis Pharmaceutical has a US patent protection (US patent no. 7 598 227) for methods of treating hyperlipidemia, lowering cholesterol and triglyceride levels with an antisense oligonucleotide hybridised within nucleotides of apolipoprotein C III (Isis Pharmaceuticals 10-K, April 2015)
  • 31 Dec 2014 Isis Pharmaceuticals has patent protection (US patent no. 7 101 993) for 2'-O-(2-methoxy) ethyl modified nucleosides (Isis pharmaceuticals 10-K, April 2015).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top